Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4E | P06730 | 4/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6555690 | 0.84 | POLB (0.59) | EIF4ETSHRPOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL6555682 | 0.84 | POLB (0.59) | EIF4ETSHRPOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL4439669 | 0.82 | TSHR (0.59) | EIF4ETSHRGAAMEN1KMT2A | |
| SCHEMBL29120749 | 0.81 | MAPT (0.57) | EIF4ETSHRGAAMEN1KMT2A | |
| SCHEMBL4371510 | 0.81 | GAA (0.59) | TSHRGAACYP3A4POLBKMT2A | |
| SCHEMBL11189916 | 0.80 | TSHR (0.72) | TSHRCYP3A4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL406111 | 0.79 | TSHR (0.60) | TSHRKCNMA1GAACYP3A4SMN1; SMN2 | |
| SCHEMBL6702122 | 0.79 | MYC (0.58) | EIF4ETSHRGAACYP3A4POLB | |
| Phthalic Acid SCHEMBL10580388 | 0.79 | TSHR (0.59) | EIF4ETSHRKCNMA1GAACYP3A4 | |
| SCHEMBL2960968 | 0.78 | ALDH1A1 (0.61) | TSHRKCNMA1CYP3A4POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1181014-B1 | HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2007-05-23 | — | — | EP | disclosed |
| US-6927227-B2 | Heterocyclic containing biphenyl aP2 inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-09 | — | — | US | disclosed |
| US-20030199563-A1 | Heterocyclic containing biphenyl aP2 inhibitors and method | ROBL JEFFREY A (US) | 2003-10-23 | — | — | US | disclosed |
| US-6548529-B1 | AP2 (adipocyte fatty binding protein); biphenyl-substituted pyrazoles of given formula; treating diabetes and related diseases; mixtures with other antidiabetic agents such as metformin, glyburide, troglitazone and/or insulin | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-15 | — | — | US | disclosed |
| EP-1181014-A4 | HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2002-06-05 | — | — | EP | disclosed |
| EP-1181014-A1 | HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-02-27 | — | — | EP | disclosed |
| WO-2000059506-A1 | HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB CO. (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199563-A1 | Heterocyclic containing biphenyl aP2 inhibitors and method | AP2B1, AP2A2, AP2A1 | EIF4E 2137/4885TSHR 734/4885KCNMA1 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.